Revolution Medicines Officer Anthony Mancini Sells $743K in RVMD Under Rule 10b5-1 Plan

Insider Trading Summary: Revolution Medicines, Inc. (NASDAQ: RVMD)

1. Overview of Transactions

On September 24 and September 25, 2026, Anthony Mancini, Chief Global Commercialization Officer of Revolution Medicines, Inc., executed transactions involving the exercise of options and subsequent sale of common stock:

• September 24, 2026: Sold 587 shares of Common Stock at $200.00 per share for gross proceeds of $117,400.00.
• September 25, 2026: Exercised stock options to acquire 3,121 shares of Common Stock at an exercise price of $33.62 per share ($104,928.02 total cost).
• September 25, 2026: Sold 3,121 shares of Common Stock at $200.54 per share for gross proceeds of $625,885.34.

In total, Mr. Mancini disposed of 3,708 shares for aggregate proceeds of $743,285.34 (net gain of ~$638,357 before taxes).

2. Plan Details and Ownership Impact

• Rule 10b5-1 Trading Plan: All transactions were conducted pursuant to a pre-arranged Rule 10b5-1 trading plan established on June 11, 2026.
• Post-Transaction Holdings: Following these transactions, Mr. Mancini directly holds 39,765 shares of common stock, which includes 39,575 unvested restricted stock units (RSUs). He also retains 93,625 stock options subject to ongoing vesting schedules.

3. Market and Sentiment Implications

• Significance Rating: Low.
• The bulk of the sale (3,121 shares) was an immediate exercise-and-sell of in-the-money options, combined with a modest sale of 587 existing shares.
• Because the transactions were executed under a pre-scheduled Rule 10b5-1 plan, they represent standard executive compensation realization rather than a discretionary market-timing trade.